Intranasal insulin has shown promise in improving cognition in early Alzheimer's disease and type 2 diabetes, supporting the concept that restoring insulin sensitivity can mitigate neurodegeneration. The gene discussed is INS; the disease is early-onset autosomal dominant Alzheimer disease.